Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-716P is a pseudogene of the U6 small nuclear RNA (snRNA) gene family. Pseudogenes are genomic DNA sequences similar to normal genes but nonfunctional; they arise from gene duplication or retrotransposition and typically lack the ability to produce functional RNA or protein. U6 small nuclear RNAs are key components of the spliceosome complex necessary for pre-mRNA splicing, but RNU6-716P itself is not active in this role and is considered functionally inert[9][8][3][10]. As such, it has no therapeutic, diagnostic, or biomarker relevance. Summary of critical points: - RNU6-716P is a noncoding, nonfunctional pseudogene—not a protein, not an active RNA, and not a molecular drug target[9][8][10]. - No disease, drug, or biomarker associations exist for this pseudogene. - Designation as a “target” is incorrect; it is simply a genetic remnant without biological activity in normal or disease physiology[9][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 716, pseudogene (RNU6-716P).